Conexeu Sciences Inc. — Form SCHEDULE 13D
Filed August 18, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 18/100
What the filing says
Jeffrey Nathan Sharpe filed a Schedule 13D with the SEC on 2026-08-18 regarding beneficial ownership in Conexeu Sciences Inc. (medical devices, SIC 3842). The filing discloses Sharpe's address as Delta, British Columbia, Canada. Specific share count, percentage ownership, acquisition amount, and transaction details are not provided in the header document text.
Why this rating
Schedule 13D filing is routine disclosure. No material acquisition details, share counts, or ownership percentages disclosed in excerpt; cannot assess actual economic significance without full filing text.
See more from August 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.